Bristol-myers Squibb Compnay

Sunanda A Ranadive

Krishnaswamy Srinivas Raghavan

Jack Z Gougoutas

John D DiMarco

Sailesh A Varia

William L Parker

Ann W Newman

Martha Davidovich

Nemichand B Jain

Robert Abramowitz

Veronique Trognon

Kenneth S Bembenek

Richard G Corrao

Loutfy Benkerrour

Luigi Esposito

There is provided in accordance with the present invention the quinolone antibacterial gatifloxacin adequately taste-masked so that it can be utilized for pediatric formulations. A crystalline co-precipitate of gatifloxacin and one or both of stearic acid and palmitic acid in a narrow weight ratio has been found to effectively mask the bitter taste of gatifloxacin. The taste of gatifloxacin is effectively masked in the mouth and in aqueous suspension through a full dosage cycle, typically fourteen days. Gatifloxacin in the subject crystalline co-precipitates has been found to be readily available for absorption from the stomach.

Pediatric formulation of gatifloxacin

Gatifloxacin pentahydrate

A three component pharmaceutical formulation of one or more pharmacologically active substances such that greater than 80% of the pharmacologically active substance will be released in the large intestine. The first component comprises the pharmacologically active substance, microcrystalline cellulose, a pH-sensitive polymer, and optionally an osmotic agent. The second component is a delayed release coating, and the third component is an enteric coating.

Colonic drug delivery system

Growing community of inventors

East Brunswick, NJ, United States of America

Sunanda A Ranadive